SSRI use increases HMO drug spending 21% but cuts overall treatment costs by 18% -- Express Scripts data.
SSRI TREATMENTS INCREASE DRUG EXPENDITURES 21%, CUT OVERALL COSTS for treatment of nonpsychotic depression by 18% in a comparison of 1993-1994 and 1994-1995 data from a large midwestern HMO. The analysis of average spending in the two periods was conducted by the St. Louis-based pharmacy benefit manager Express Scripts for one of its HMO clients.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth